title: Targeting activated platelets and fibrinolysis: hitting two birds with one stone.
authors.affiliation: From the Department of Laboratory Medicine, Keenan Research Centre for Biomedical Science of St. Michael's Hospital (A.R., X.X., E.C.R., H.N.), Department of Laboratory Medicine and Pathobiology (X.X., H.N.), and Departments of Medicine and Physiology (H.N.) University of Toronto, Toronto, ON, Canada; and Toronto Platelet Immunobiology Group (A.R., X.X., E.C.R., H.N.) and Canadian Blood Services (H.N.), Toronto, ON, Canada.
authors.forename: Adili
authors.initials: A
authors.lastname: Reheman
authors.forename: Xiaohong
authors.initials: X
authors.lastname: Xu
authors.forename: Emily C
authors.initials: EC
authors.lastname: Reddy
authors.forename: Heyu
authors.initials: H
authors.lastname: Ni
mesh_terms: D000818:Animals; D001792:Blood Platelets / Q000187:drug effects*; D002339:Carotid Arteries / Q000000981:diagnostic imaging*; D005343:Fibrinolytic Agents / Q000627:therapeutic use*; D057127:Single-Chain Antibodies / Q000627:therapeutic use*; D013923:Thromboembolism / Q000188:drug therapy*; D014463:Ultrasonography; D014568:Urokinase-Type Plasminogen Activator / Q000627:therapeutic use*
chemical_list: D005343:Fibrinolytic Agents; D057127:Single-Chain Antibodies; D014568:Urokinase-Type Plasminogen Activator
keywords: Editorials; blood platelets; fibrinolysis; thrombolytic therapy; thrombosis